FDA Issues Warning as Copaxone and Glatopa Linked to Delayed and Severe Allergic Reactions
Washington, D.C. – The U.S. Food and Drug Administration (FDA) has issued a warning regarding the risk of anaphylaxis linked to the use of multiple sclerosis drugs Copaxone and its generic counterpart, Glatopa. This severe allergic reaction necessitates immediate medical intervention and can be potentially life-threatening. Anaphylaxis is characterized by symptoms that rapidly escalate, including difficulty breathing, swelling of the face, lips, or throat, and a sudden drop in blood pressure. These reactions are often …